The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Lisa Richardson named director of CDC Division of Cancer Prevention and Control

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

LISA RICHARDSON was named director of the CDC Division of Cancer Prevention and Control.

Richardson served for over a decade in medical and scientific leadership roles in the division and will rejoin the center Nov. 16.

She first joined CDC in 1997 as medical officer in DCPC’s National Breast and Cervical Cancer Early Detection Program and was then selected as medical officer of the Hematologic Diseases Branch in the National Center for Infectious Diseases.

She left CDC in late 2000 to practice clinical care and serve as assistant professor at the University of Florida’s School of Medicine. Richardson then returned to CDC in 2004 as medical officer and served as lead of the Scientific Support and Clinical Translation Team in the Comprehensive Cancer Control Branch and as the division’s associate director for science. She then left DCPC in April 2013 to direct the Division of Blood Disorders in the National Center for Birth Defects and Developmental Disabilities.

Pamela Protzel Berman, who served as acting director of DCPC, will return to her full-time duties as DCPC’s deputy director.

Table of Contents

YOU MAY BE INTERESTED IN

Book Review

What are The CheckPoints movin’ and groovin’ to this summer?
Join the journal club with the best bops: We asked SITC’s 13-piece band of medical musicians for the top papers and songs of the summer

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.
By Sara Willa Ernst and Paul Goldberg
Guest Editorial

The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and why
Drug development must convene a forum for candid, cross-sector discussion

At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
By Richard L. Schilsky, H. Kim Lyerly, Thomas R. Fleming and Renzo Canetta
ClinicalGuest Editorial

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical framework
Developers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care

In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 
By Viktor Clark, Sean M. Dozier, AnnaLynn M. Williams, Cynthia M. Rand and Lee A. Kehoe
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account